In ear­ly look at ASH ab­stracts, BeiGene touts Brukin­sa da­ta, Cel­lec­tis com­pares in-house CAR-T to CD­MO CAR-T

The non-late break­ing ab­stracts for next month’s Amer­i­can So­ci­ety of Hema­tol­ogy meet­ing were re­leased on Thurs­day, giv­ing a peek in­to what will be some of the most heav­i­ly scru­ti­nized da­ta in San Diego in ear­ly De­cem­ber.

Be­low are a hand­ful of the most no­table:

Brukin­sa still out­per­form­ing Im­bru­vi­ca in CLL: BeiGene nabbed FDA ap­proval for Brukin­sa in re­lapsed/re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia in Jan­u­ary, and the com­pa­ny plans to show off how its drug con­tin­ues to main­tain deep­er re­spons­es than Ab­b­Vie and John­son & John­son’s Im­bru­vi­ca over longer pe­ri­ods of time. At three years of fol­low-up, pro­gres­sion-free sur­vival rates were 65.8% for Brukin­sa and 54.3% for Im­bru­vi­ca, and over­all sur­vival rates were 82.6% (Brukin­sa) and 79.7% (Im­bru­vi­ca). Haz­ard ra­tios for PFS and OS, re­spec­tive­ly, were 0.67 and 0.76. All fig­ures re­main con­sis­tent with what BeiGene pre­sent­ed at ASH last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER